Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome injection in advanced breast cancer
NCT04728035Phase 1Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan liposome in breast cancer (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Incidence of treatment-related adverse events and serious adverse events, Dose Limiting Toxicity up to 28 days and 2 more. Started May 2021; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04728035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728035.